-- Eupraxia Pharmaceuticals (EPRX.TO) Tuesday reported the latest 36-week results for the highest dose from the dose escalation portion of the Resolve trial.
Patients in Cohort 9 demonstrated a "robust" response in both tissue health and symptom response compared to their baseline levels, the company said. Clinical remission in symptoms was maintained in 66% of the patients in Cohort 9 at week 36. This level of remission was first achieved at week 8 and was maintained through 36 weeks, a statement added.
Phase 1b/2a of the Resolve trial is a multicenter, dose-escalation study testing the efficacy and safety of Eupraxia's EP-104GI in adults with active eosinophilic esophagitis (EoE.) The treatment is administered as a single dose via four to 20 esophageal wall injections, and continues to be well tolerated by patients receiving the drug.
"This data is consistent with the compelling results we observed at earlier timepoints at this dose level, highlighting the potential to achieve both strong and durable responses after a single administration of EP-104GI. We are also reassured by the excellent safety outcomes across all doses in the trial as we continue to observe no indication of drug related SAEs or spikes in glucose or cortisol," said chief executive Dr James Halliwell.
The top-line data from the Phase 2b part of the Resolve trial is expected in the fourth quarter of this year.
Eupraxia shares closed up $0.16, to $9.90, on Monday, on the Toronto Stock Exchange.